Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD

Anticholinergics; Chronic obstructive pulmonary disease (COPD); Irisin; Long acting muscarinic receptor antagonist (LAMA); Article; Charlson Comorbidity Index; Short Form 36

Abstract :

[en] Long acting muscarinic antagonists (LAMA) are currently considered the therapeutic mainstay for patients with COPD and have been shown to improve clinical outcomes including symptoms, exercise capacity and airflow limitation. Irisin, is a newly discovered hormone-like myokine generated by skeletal muscle cells in response to exercise and it is suggested to regulate energy expenditure and exercise capacity. The aim of the present study was to investigate if treatment with LAMA alters serum irisin levels in patients with COPD. Irisin was assessed by ELISA in the serum of 506 patients with COPD, GOLD II-IV, with a smoking history >10 PY, who were included in the PROMISE-COPD cohort. The effect of inhaled LAMA on serum irisin levels was evaluated in a proof-of-concept cohort of 40 COPD patients. Univariate linear regression analysis revealed that there was a significant negative association of irisin with age-adjusted Charlson score (p = 0.003) and a positive association of irisin with 6-min walking distance (6MWD) (p = 0.018) and treatment with LAMA (p = 0.004) but not with LABA or ICS. Multivariate analysis revealed that the association of irisin with LAMA treatment remains significant after adjustment for age-adjusted score and 6MWD. In the proof-of-concept cohort a single inhalation of LAMA stimulated serum irisin levels after 4 h. These findings imply that treatment of COPD patients with LAMA increase circulating irisin, thus explaining some of the beneficial extra-pulmonary effects of these drugs when used in the treatment of COPD. © 2017

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Mandal, Jyotshna; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Roth, Michale; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Papakonstantinou, Eleni; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Sun, Qingzhu; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Costa, Luigi; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Boeck, Lucas; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Scherr, Andreas; Clinic of Pulmonary Medicine, University Hospital Basel and Respiratory Cell Research, Department of Biomedicine, University of Basel, Basel, Switzerland

Rakic, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Ophtalmologie

Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie

Milenkovic, B.; Pneumology, Institute for Pulmonary Diseases, Belgrade, Serbia

More authors (10 more)

Language :

English

Title :

Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD

Publication date :

2018

Journal title :

Pulmonary Pharmacology and Therapeutics

ISSN :

1094-5539

eISSN :

1522-9629

Publisher :

Academic Press

Volume :

Pages :

111-116

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 12 November 2019

Statistics

Number of views

140 (5 by ULiège)

Number of downloads

119 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Wedzicha, J.A., Decramer, M., Ficker, J.H., et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 1 (2013), 199–209.
Vogelmeier, C.F., Bateman, E.D., Pallante, J., et al. Efficacy and safety of once-daily QVA149 compared with twice- daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 1 (2013), 51–60.
Wedzicha, J.A., Banerji, D., Chapman, K.R., et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 374 (2016), 2222–2234.
Vogelmeier, C., Paggiaro, P.L., Dorca, J., et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur. Respir. J. 48 (2016), 1030–1039.
Buhl, R., Maltais, F., Abrahams, R., et al. Tiotropium and olodaterol fixed- dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 45 (2015), 969–979.
Barnes, P.J., Muscarinic receptor subtypes in airways. Life Sci. 52 (1993), 521–527.
Eglen, R.M., Hegde, S.S., Watson, N., Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. 48 (1996), 531–565.
O'Donnell, D.E., Fluge, T., Gerken, F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 23 (2004), 832–840.
Santus, P., Buccellati, C., Centanni, S., et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol. Res. 66 (2012), 343–348.
Miravitlles, M., Anzueto, Jardim, J.R., Optimizing bronchodilation in the prevention of COPD exacerbations. Respir. Res. 18 (2017), 125–149.
Zhong, J., Roth, R., Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Ther. Clin. Risk Manag. 10 (2014), 449–453.
Cazzola, M., Molimard, M., The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 23:4 (2010), 257–267.
Berton, D.C., Santos, Á.H., Bohn, I. Jr., et al. Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study. J. Bras. Pneumol. 42:5 (2016), 367–373 Sep-Oct.
Bostrom, P., Wu, J., Jedrychowski, M.P., et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481 (2012), 463–468.
Teufel, A., Malik, N., Mukhopadhyay, M., Westphal, H., Frcp1 and Frcp2, two novel fibronectin type III repeat containing genes. Gene 297 (2002), 79–83.
Loffler, D., Muller, U., Scheuermann, K., et al. Serum irisin levels are regulated by acute strenuous exercise. J. Clin. Endocrinol. Metab. 100:4 (2015), 1289–1299.
Tsuchiya, Y., Ando, D., Goto, K., et al. High-intensity exercise causes greater irisin response compared with low-intensity exercise under similar energy consumption. Tohoku J. Exp. Med. 233 (2014), 135–140.
Ijiri, N., Kanazawa, H., Asai, K., Watanabe, T., Hirata, K., Irisin, a newly discovered myokine, is a novel biomarker associated with physical activity in patients with chronic obstructive pulmonary disease. Respirology 20:4 (2015), 612–617.
Kureya, Y., Kanazawa, H., Ijiri, N., et al. Down-regulation of soluble alpha-Klotho is associated with reduction in serum irisin levels in chronic obstructive pulmonary disease. Lung 194 (2016), 345–351.
Qiu, S., Cai, X., Sun, Z., et al. Chronic exercise training and circulating irisin in adults: a meta-analysis. Sports Med. 45 (2015), 1577–1588.
Boeck, L., Gensmer, A., Nyilas, S., et al. Single-breath washout tests to assess small airway disease in COPD. Chest 150:5 (2016), 1091–1100.
Kelly, D.P., Medicine. Irisin, light my fire. Science 336 (2012), 42–43.
Timmons, J.A., Baar, K., Davidsen, P.K., Atherton, P.J., Is irisin a human exercise gene?. Nature 488 (2012), E9–E10 discussion E10–11.
Greulich, T., Nell, C., Koepke, J., et al. Benefits of whole body vibration training in patients hospitalised for COPD exacerbations - a randomized clinical trial. BMC Pulm. Med., 14, 2014, 60.
Moreno-Navarrete, J.M., Ortega, F., Serrano, M., et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J. Clin. Endocrinol. Metab. 98 (2013), E769–E778.
Choi, Y.K., Kim, M.K., Bae, K.H., et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res. Clin. Pract. 100 (2013), 96–101.
Huh, J.Y., Panagiotou, G., Mougios, V., et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61 (2012), 1725–1738.
Gouni-Berthold, I., Berthold, H.K., Huh, J.Y., et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One, 8, 2013, e72858.
Lecker, S.H., Zavin, A., Cao, P., et al. Expression of the irisin precursor FNDC5 in skeletal muscle correlates with aerobic exercise performance in patients with heart failure. Circ. Heart Fail. 5 (2012), 812–818.
Fabbri, L.M., Rabe, K.F., From COPD to chronic systemic inflammatory syndrome?. Lancet 370 (2007), 797–799.
Mador, M.J., Kufel, T.J., Pineda, L.A., et al. Effect of pulmonary rehabilitation on quadriceps fatiguability during exercise. Am. J. Respir. Crit. Care Med. 163 (2001), 930–935.